Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

3.4K
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
3.4K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

2.2K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
2.2K
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

784
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
784
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

1.2K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.2K
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

1.2K
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
1.2K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

1.3K
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Cervical and Orofacial Variable Dystonia in Levodopa-Naïve PRKN Parkinson's Disease.

Movement disorders clinical practice·2026
Same author

Transition from paediatric to adult care in paediatric-onset neurological disorders in Europe: A survey and scoping review.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2026
Same author

Pathogenic Variants in the PRKRA Gene Can Result in a Rapid-Onset Dystonia-Parkinsonism-like Phenotype.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Fronto-medial theta instability error signal correlates with postural sway in Parkinson's disease and progressive supranuclear palsy.

Journal of the neurological sciences·2026
Same author

The Assessment of RAB32 p.Ser71Arg Variant Prevalence in Parkinson's Disease Across Selected African, European, and South American Cohorts.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Persisting or Worsening Impulse Control Disorders in Parkinson's Disease Following a Switch to Subcutaneous Foslevodopa-Foscarbidopa.

Movement disorders clinical practice·2026
Same journal

Predictive ability of the Hammersmith Neonatal Neurological Examination for identifying severe neurodevelopmental impairment in infants born very preterm.

Developmental medicine and child neurology·2026
Same journal

Neuropathic pain in cerebral palsy and related genetic conditions: A scoping review of prevalence, characteristics, and management.

Developmental medicine and child neurology·2026
Same journal

Hammersmith Infant Neurological Examination global scores for predicting neurodevelopmental outcomes after 2 years of age: A systematic review and meta-analysis.

Developmental medicine and child neurology·2026
Same journal

Seizure worsening and sodium channel blockers in HCN1-related epilepsies: A case series.

Developmental medicine and child neurology·2026
Same journal

What is the impact of childhood-onset disability research - and what should it be?

Developmental medicine and child neurology·2026
Same journal

Sleep disturbances in children with cerebral palsy, their siblings, and parents: A qualitative descriptive study.

Developmental medicine and child neurology·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
10:41

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

7.5K

Status dystonicus: a practice guide.

Nicholas M Allen1, Jean-Pierre Lin, Tim Lynch

  • 1Department of Paediatric Neurology and Clinical Neurophysiology, Children's University Hospital, Dublin, Ireland.

Developmental Medicine and Child Neurology
|December 6, 2013
PubMed
Summary
This summary is machine-generated.

Status dystonicus, a critical movement disorder emergency, requires prompt recognition and tailored management. Early intervention and intensive care sedation are key to managing life-threatening spasms while specific treatments take effect.

More Related Videos

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

25.1K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.6K

Related Experiment Videos

Last Updated: May 5, 2026

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
10:41

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

7.5K
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

25.1K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.6K

Area of Science:

  • Neurology
  • Movement Disorders

Background:

  • Status dystonicus is a rare but life-threatening movement disorder emergency.
  • Prompt assessment and tailored management are crucial for patient outcomes.

Purpose of the Study:

  • To provide an overview of the clinical presentation of status dystonicus.
  • To suggest an evidence-based management approach for this condition.

Main Methods:

  • Review of clinical presentation and management strategies for status dystonicus.
  • Discussion of temporizing measures, sedation, and dystonia-specific treatments.

Main Results:

  • Early recognition and dystonia action plans may prevent progression.
  • Intensive care unit (ICU) or high dependency unit (HDU) sedation is vital for immediate spasm control.
  • Intrathecal baclofen or deep brain stimulation may be considered for refractory cases.

Conclusions:

  • Effective management involves a multi-faceted approach including sedation and specific anti-dystonia therapies.
  • Further research into the epidemiology and clinical evolution of status dystonicus is essential.